SELAX PARTNERS WITH BIOHAVEN
Investment and scientific partnerships in the GCC, North Africa and Turkey
Saudi Arabia and its neighbors are investing in the capabilities needed to develop medicines, alongside expanding access to existing treatments. For US biotechnology companies, this creates an opportunity to build partnerships that contribute to their global business. For regional investors and institutions, it offers a stake in the science, companies and financial returns behind those medicines.
Across the GCC, North Africa and Turkey, investment is taking several forms. Gulf institutions are financing US drug developers and acquiring pharmaceutical businesses. Manufacturers are expanding production and commercial relationships, while universities are connecting their research with international drug-development expertise. The opportunity is to bring these strengths together in partnerships that benefit both the companies and the region.
An established market for medicines
There is already a substantial medicines business in the region. According to Daleel, the investment information platform developed by Saudi Arabia’s National Industrial Development and Logistics Program, the Saudi pharmaceutical market was approximately US$12.4 billion in 2024, with imports accounting for 64 percent of its value. Turkey has an established pharmaceutical manufacturing base alongside continued demand for imported biologics and specialty therapies. [1, 2]
In Turkey, locally manufactured medicines accounted for 88 percent of units sold in 2023 but 57 percent of sales value. Imported products, including biologics and specialty therapies, accounted for a greater share of spending relative to their volume. This combination of local production and demand for higher-value treatments gives international companies several ways to participate. [2]
Egypt shows how local production can serve a wider market. In December 2024, Lilly and EVA Pharma announced approval and release of insulin glargine manufactured in Egypt. Their collaboration, announced in 2022, combined discounted supplies of the active pharmaceutical ingredient with technology transfer provided without charge. EVA Pharma completed a biologics facility and released its first batch. The companies aim to reach at least one million people annually by 2030 in low- and middle-income countries, predominantly in Africa. [3]
The commercial opportunity therefore extends across several markets, with different roles for research, production and sales. Purchasing power, reimbursement and the treatments patients can access shape the business in each country.
Regional capital is already investing
Gulf investors are already backing international biotechnology companies. In September 2023, Qatar Investment Authority led a US$250 million private placement in BridgeBio Pharma alongside other institutional investors, supporting the US company’s development of genetic medicines. [4]
Saudi Arabia’s Hevolution Foundation is investing in drug development linked to its healthspan mission. In March 2024, it announced a US$20 million investment as the lead investor in Aeovian Pharmaceuticals’ US$50 million Series A extension. The financing supported a platform of selective mTORC1 inhibitors for rare and age-related diseases, and Hevolution’s chief investment officer joined the board. The foundation’s involvement combines financial investment with an active role in the company’s development. [5]
Mubadala has taken a different approach through ownership of pharmaceutical businesses. Its acquisition of KELIX bio closed in September 2024, bringing together manufacturing businesses in Egypt, Morocco, India and Malta with exports to more than 50 countries. Subsequent acquisitions added pharmaceutical assets in the UAE. KELIX bio’s focus on complex generics connects Gulf investment with established production and commercial operations across borders. [6]
These transactions show regional investors taking stakes in both the development of new medicines and the businesses that manufacture and supply existing treatments. They are building positions across the industry, with opportunities to earn returns as those companies grow.
Biotechnology is part of the economic agenda
Saudi Arabia’s National Biotechnology Strategy sets out an ambition for regional leadership by 2030 and a global role by 2040. It targets approximately 11,000 quality jobs by 2030 and 55,000 by 2040 across vaccines, biomanufacturing, genomics and agricultural biotechnology. The strategy connects healthcare needs with the development of an industry that can employ skilled people and create new businesses. [7]
Abu Dhabi’s HELM (Health, Endurance, Longevity and Medicine) cluster brings research, development, manufacturing and commercialization into the same economic agenda. Launched in April 2025, it aims to attract approximately US$11.5 billion in investment and contribute approximately US$25.6 billion to Abu Dhabi’s GDP by 2045. These targets cover biotechnology, pharmaceuticals, medical technology and digital health. [8]
This gives regional institutions several reasons to invest. A development partnership can generate financial returns while building scientific expertise, creating skilled employment or strengthening domestic production. Those benefits can support a sustained commitment to the industry.
Experienced drug developers have a useful role in that process. They bring the judgment needed to turn research into development programs, along with the experience of building teams and taking medicines through clinical and regulatory stages. Working with them can help regional institutions put their research and infrastructure to commercial use.
Connecting regional science with drug development
Biohaven’s relationship with King Abdullah University of Science and Technology, or KAUST, offers an example. In its January 2026 announcement at the J.P. Morgan Healthcare Conference, Biohaven disclosed a memorandum of understanding to collaborate on next-generation degrader discovery. The planned work draws on KAUST’s strengths in Smart Health, generative AI and supercomputing. [9] The collaboration builds on Biohaven’s MoDE™ and TRAP™ extracellular protein degrader platforms, which originated in research at Yale University and are now in clinical development. The lead MoDE degrader, BHV-1300, an investigational medicine, is in Phase 3 development for Graves’ disease. [9, 11]
Developing a medicine requires decisions about which scientific findings to pursue, which molecules to advance and what evidence is needed at each stage. An experienced biotechnology company brings the people and processes to make those decisions. Biohaven’s leadership team, for example, previously took the migraine medicine NURTEC ODT (rimegepant) through FDA approval and launch at Biohaven’s predecessor company, which Pfizer acquired in 2022 for approximately US$12 billion. [12] A university can contribute research expertise and technology that broaden what the company can investigate. Bringing the two together gives promising science a clearer path toward development.
For Saudi Arabia, the value can extend beyond any single program. Scientists gain experience working within a drug-development process. Research can lead to new discoveries and future development opportunities. Over time, that work can help build the local teams and capabilities needed to sustain a biotechnology industry.
For Biohaven, the relationship offers a way to connect its drug-discovery and development expertise with complementary capabilities at KAUST, with the aim of accelerating the development of next-generation degraders for patients with immune-mediated diseases. It reflects the wider opportunity for globally minded US companies to build scientific partnerships in the region that contribute to their international business.
The financial case extends beyond local sales
The financial opportunity extends beyond the medicines sold within the region. Partners that invest in development and contribute scientific expertise can share in the value of treatments sold globally. Their ownership stakes and commercial rights determine how they participate in those returns.
For regional investors and institutions, this creates a connection between global commercial returns and domestic economic development. An investment can support a medicine with international potential while helping build scientific expertise and commercial capabilities at home. The experience gained can also support future programs and businesses.
For US biotechnology companies, a regional partnership can add capital, research capabilities and access to new markets. Sharing development investment can allow a company to advance more of its promising science. When that investment is made at the program or venture level, it is also non-dilutive to the company’s shareholders. Relationships with universities and healthcare institutions can add scientific and clinical capacity, while local commercial partners can support expansion into new markets.
Both sides have an interest in making the programs and the business more valuable. The US company can expand what it develops and where it operates. Regional partners can earn returns from successful medicines and build expertise that remains useful beyond the initial investment.
Examples of investment and partnership
| Participants and Date | Disclosed Milestone | Economic Significance |
|
Qatar and US BridgeBio 2023 |
US$250 million private placement led by QIA alongside other institutional investors. [4] | Corporate equity exposure to global drug development. |
|
Saudi Arabia and US Hevolution and Aeovian 2024 |
US$20 million Hevolution investment announced within a US$50 million financing extension; board participation. [5] | Investment in a defined therapeutic platform and scientific mission. |
|
UAE and North Africa Mubadala and KELIX bio 2024 |
Acquisition closed September 2024; platform included manufacturing businesses in Egypt and Morocco. [6] | Ownership of pharmaceutical operations with international markets. |
|
Egypt and US EVA Pharma and Lilly 2024 |
Locally manufactured insulin glargine approved and first batch released. [3] | Technology transfer translated into regulated production. |
|
Turkey and US Abdi İbrahim and Biogen 2025 |
Distribution partnership announced for neurological and rare-disease medicines. [10] | Commercial access to innovative therapies. |
|
Saudi Arabia and US KAUST and Biohaven 2026 |
MOU announced for next-generation degrader discovery, drawing on KAUST's technology capabilities. [9] | Scientific collaboration with regional research and computing capabilities linked to a clinical-stage degrader platform. |
Recent transactions and operating milestones show the different roles regional partners are taking.
Building a lasting biotechnology industry
The GCC, North Africa and Turkey have different strengths to contribute. The examples here connect Gulf capital with US drug development, North African manufacturing and international pharmaceutical businesses. Research partnerships add another opportunity by linking regional institutions with companies experienced in developing medicines.
The opportunity we see is to connect experienced drug developers with regional partners who want to help build the industry and participate in its success. A partnership can give a US company the resources and relationships to expand its business while giving regional investors and institutions a stake in the medicines developed together.
As these partnerships grow, they can also build an experienced scientific workforce, stronger commercial relationships and the ability to develop further programs. That is how an investment in individual companies and medicines can contribute to a lasting biotechnology industry. Ultimately, the measure of success is new medicines reaching patients, in the region and around the world.
SELAX works with international companies to develop strategic partnerships and businesses across the region. SELAX has partnered with Biohaven to support the formation of a regional joint venture across the Middle East, North Africa and Turkey (MENAT), including identifying strategic partners. selaxcap.com
Sources and data notes
Numbered references support the factual claims in the article; the interpretation of their investment significance is SELAX analysis. Selection is illustrative and does not constitute a comprehensive transaction census. This perspective is for information only. It is not investment advice and is not an offer to sell, or a solicitation of an offer to buy, any security.
1. Daleel government industrial platform. Pharmaceuticals and biotechnology market insight. The 2024 Saudi market value is approximately US$12.4bn, converted at the official pegged exchange rate. The cited local production and import shares are by value. Source
2. US International Trade Administration. Turkey Medical Technologies and Health IT. Supports Turkey’s manufacturing profile and the 2023 domestic production shares cited in the article. Source
3. Eli Lilly and Company. Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt, 17 December 2024. The 2030 patient figure is an objective, not a reported treatment outcome. Source
4. BridgeBio Pharma and SEC. US$250 million private placement announcement, 25 September 2023; subsequent Form 10-Q for the quarter ended 30 September 2023 records issuance and proceeds. QIA’s own contribution was not separately specified in the release. Source | SEC filing
5. Hevolution Foundation. US$20 million impact investment in Aeovian Pharmaceuticals, 28 March 2024. Distinguishes Hevolution’s investment from the US$50 million total Series A extension. Source
6. EBRD and Emirates News Agency. EBRD announcement of the KELIX bio sale, 25 March 2024, describes the operating footprint. WAM, 14 October 2024, confirms September closing and subsequent UAE acquisitions. Source | Closing confirmation
7. Saudi Ministry of Health and Saudipedia. National Biotechnology Strategy. Ministry of Health, 15 July 2025, describes sector priorities and employment targets. Saudipedia distinguishes the 2030 regional and 2040 global ambitions. These are policy targets, not investment commitments or forecasts of company returns. Source | Strategy milestones
8. Abu Dhabi Media Office. HELM launch, 15 April 2025; San Francisco office expansion, 8 May 2025. The latter states the approximately US$11.5bn investment and US$25.6bn GDP targets by 2045. Uses the official published USD equivalents; targets cover the broader cluster. Source | Cluster launch
9. Biohaven. Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference, 12 January 2026. Uses the supplied public release. No proposed JV terms or unpublished developments are included. Source
10. Abdi İbrahim and Biogen. Biogen Partners with Abdi İbrahim in Türkiye. Release dated 18 September 2025, posted 23 September 2025. Describes a distribution partnership for neurological and rare-disease medicines. Source
11. Pfizer. Pfizer Completes Acquisition of Biohaven Pharmaceuticals, 3 October 2022. Identifies the predecessor company as the maker of NURTEC ODT and states the approximately US$11.6 billion transaction value. Source